Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Decitabine Dose-Tolerance in Surgically Resectable HPV-Negative Head and Neck Cancer

NCT06997094 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06997094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06997094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Decitabine Dose-Tolerance in Surgically Resectable HPV-Negative Head and Neck Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
January 23, 2026
Completion date
November 8, 2027
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-negative squamous cell carcinoma, human papillomavirus-negative neck squamous cell carcinoma, resectable head and neck squamous cell carcinoma, resectable head and neck squamous-cell carcinoma, resectable human papillomavirus-independent head and neck mucosal squamous cell carcinoma